_id
6913050cccc777a4e85d7a8e
Ticker
IXSBF
Name
InNexus Biotechnology Inc
Exchange
OTCCE
Address
1500 Royal Centre, Vancouver, BC, Canada, V6E 4N7
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
www.ixsbio.com
Description
InNexus Biotechnology, Inc., a development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. Its DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies. The company's products in pipeline include DXL625, a monoclonal antibody in late stage pre-clinical development produced with enhanced binding kinetics and effector functions for the treatment of B cell non-Hodgkins lymphoma (NHL) and DXLr120, a recombinant DXL anti-CD20 antibody being developed for the treatment of B cell NHL cancer; DXL702, a monoclonal antibody being developed for the treatment of metastatic breast cancer; and DXL1218, which targets an antigen designated epidermal growth factor receptor that is over expressed in metastatic colorectal cancer and in squamous cell carcinomas of the head and neck. It has collaboration agreements with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is headquartered in Vancouver, Canada.
Last Close
0.0001
Volume
-
Current Price
0.0001
Change
0
Last Updated
2025-11-11T09:42:35.709Z
Image
-
Ipo Date
1998-10-16T00:00:00.000Z
Market Cap
114240
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2011-03-31
Revenue
0
Cost Of Revenue
0
Gross Profit
0
Operating Expenses
308687
Operating Income
-308687
Interest Expense
247266
Pretax Income
-555939
Net Income
-555939
Eps
-
Dividends Per Share
-
Shares Outstanding
-
Income Tax Expense
0
EBITDA
-
Total Other Income Expense Net
-
Cash
31433
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
34092
Property Plant Equipment
551801
Total Assets
3160748
Payables
1927344
Short Term Debt
6453804
Long Term Debt
262898
Total Liabilities
9581299
Equity
-6428442
Depreciation
114002
Change In Working Capital
-
Cash From Operations
-114853
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
47223
Net Change In Cash
-67630
PE
-
PB
-
ROE
8.648114115364189
ROA
-17.58884289415037
FCF
-114853
Fcf Percent
-
Piotroski FScore
1
Health Score
40
Deep Value Investing Score
1
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
0.5
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
1
Quality Investing Score
0.5
Value Investing Score
1
Quarters > 0 > quarter
2011-03-31
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
0
Quarters > 0 > income Statement > gross Profit
0
Quarters > 0 > income Statement > operating Expenses
308687
Quarters > 0 > income Statement > operating Income
-308687
Quarters > 0 > income Statement > interest Expense
247266
Quarters > 0 > income Statement > pretax Income
-555939
Quarters > 0 > income Statement > net Income
-555939
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
0
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > balance Sheet > cash
31433
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
34092
Quarters > 0 > balance Sheet > property Plant Equipment
551801
Quarters > 0 > balance Sheet > total Assets
3160748
Quarters > 0 > balance Sheet > payables
1927344
Quarters > 0 > balance Sheet > short Term Debt
6453804
Quarters > 0 > balance Sheet > long Term Debt
262898
Quarters > 0 > balance Sheet > total Liabilities
9581299
Quarters > 0 > balance Sheet > equity
-6428442
Quarters > 0 > cash Flow > net Income
-555939
Quarters > 0 > cash Flow > depreciation
114002
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-114853
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
47223
Quarters > 0 > cash Flow > net Change In Cash
-67630
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
8.648114115364189
Quarters > 0 > ratios > ROA
-17.58884289415037
Quarters > 0 > ratios > FCF
-114853
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
40
Quarters > 1 > quarter
2010-12-31
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
0
Quarters > 1 > income Statement > gross Profit
0
Quarters > 1 > income Statement > operating Expenses
411041
Quarters > 1 > income Statement > operating Income
-411041
Quarters > 1 > income Statement > interest Expense
505482
Quarters > 1 > income Statement > pretax Income
-799750
Quarters > 1 > income Statement > net Income
-799750
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
0
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > balance Sheet > cash
99063
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
99063
Quarters > 1 > balance Sheet > property Plant Equipment
665455
Quarters > 1 > balance Sheet > total Assets
3339721
Quarters > 1 > balance Sheet > payables
1903551
Quarters > 1 > balance Sheet > short Term Debt
4057794
Quarters > 1 > balance Sheet > long Term Debt
337965
Quarters > 1 > balance Sheet > total Liabilities
9274384
Quarters > 1 > balance Sheet > equity
-5942554
Quarters > 1 > cash Flow > net Income
-799750
Quarters > 1 > cash Flow > depreciation
90904
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-64647
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
147074
Quarters > 1 > cash Flow > net Change In Cash
82427
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
13.458018219102428
Quarters > 1 > ratios > ROA
-23.94661110913157
Quarters > 1 > ratios > FCF
-64647
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
44
Quarters > 2 > quarter
2010-09-30
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
0
Quarters > 2 > income Statement > gross Profit
0
Quarters > 2 > income Statement > operating Expenses
353802
Quarters > 2 > income Statement > operating Income
-353802
Quarters > 2 > income Statement > interest Expense
620105
Quarters > 2 > income Statement > pretax Income
-973897
Quarters > 2 > income Statement > net Income
-973897
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
0
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > balance Sheet > cash
16636
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
20976
Quarters > 2 > balance Sheet > property Plant Equipment
756011
Quarters > 2 > balance Sheet > total Assets
3352538
Quarters > 2 > balance Sheet > payables
1866119
Quarters > 2 > balance Sheet > short Term Debt
3720883
Quarters > 2 > balance Sheet > long Term Debt
373216
Quarters > 2 > balance Sheet > total Liabilities
8919680
Quarters > 2 > balance Sheet > equity
-5575033
Quarters > 2 > cash Flow > net Income
-973897
Quarters > 2 > cash Flow > depreciation
96423
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-145020
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
161228
Quarters > 2 > cash Flow > net Change In Cash
16208
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
17.468901080944274
Quarters > 2 > ratios > ROA
-29.049543957443586
Quarters > 2 > ratios > FCF
-145020
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
47
Quarters > 3 > quarter
2010-06-30
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
0
Quarters > 3 > income Statement > gross Profit
0
Quarters > 3 > income Statement > operating Expenses
702851
Quarters > 3 > income Statement > operating Income
-702851
Quarters > 3 > income Statement > interest Expense
753715
Quarters > 3 > income Statement > pretax Income
-1911953
Quarters > 3 > income Statement > net Income
-1911953
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
0
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > balance Sheet > cash
428
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
8962
Quarters > 3 > balance Sheet > property Plant Equipment
852086
Quarters > 3 > balance Sheet > total Assets
3436946
Quarters > 3 > balance Sheet > payables
2119210
Quarters > 3 > balance Sheet > short Term Debt
3363908
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
8564875
Quarters > 3 > balance Sheet > equity
-5135820
Quarters > 3 > cash Flow > net Income
-1911953
Quarters > 3 > cash Flow > depreciation
105619
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
-152319
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-75067
Quarters > 3 > cash Flow > cash From Financing
222486
Quarters > 3 > cash Flow > net Change In Cash
-4900
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
37.227803933938496
Quarters > 3 > ratios > ROA
-55.629416348118355
Quarters > 3 > ratios > FCF
-152319
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
49
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
8.648114115364189
Profitability > metrics > ROA
-1630.7022175290392
Profitability > final Score
32
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-1.2484005079549958
Risk > final Score
25
Risk > verdict
High
Liquidity > metrics > Current Ratio
0.004067700510717625
Liquidity > metrics > Quick Ratio
0.004067700510717625
Liquidity > final Score
10
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
42
Prev Profitabilities > 1
50
Prev Profitabilities > 2
55
Prev Risks > 0
27
Prev Risks > 1
28
Prev Risks > 2
26
Prev Liquidities > 0
11
Prev Liquidities > 1
10
Prev Liquidities > 2
10
Updated At
2026-01-20T22:03:43.452Z
InNexus Biotechnology, Inc., a development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. Its DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies. The company's products in pipeline include DXL625, a monoclonal antibody in late stage pre-clinical development produced with enhanced binding kinetics and effector functions for the treatment of B cell non-Hodgkins lymphoma (NHL) and DXLr120, a recombinant DXL anti-CD20 antibody being developed for the treatment of B cell NHL cancer; DXL702, a monoclonal antibody being developed for the treatment of metastatic breast cancer; and DXL1218, which targets an antigen designated epidermal growth factor receptor that is over expressed in metastatic colorectal cancer and in squamous cell carcinomas of the head and neck. It has collaboration agreements with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is headquartered in Vancouver, Canada.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2011-03-31)
Health Score
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of InNexus Biotechnology Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2011-03-31)
(Last Updated 2011-03-31)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
(Last Updated 2011-03-31)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2011-03-31)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.